A clinical-stage biotechnology company focused on developing therapies for central nervous system disorders, particularly major depressive disorder and other neuropsychiatric conditions. Its lead program, REL-1017 (esmethadone), has been studied as a rapid-acting oral treatment for depression. Inves...
This page tracks all publicly disclosed congressional trades in Relmada Therapeutics, Inc. (RLMD), a company in the Healthcare sector. 1 member of Congress has disclosed trades in this stock, including 1 purchase and 1 sale. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-11-08 | Christopher L. Jacobs | buy | $1K – $15K |